Dechra Pharmaceuticals Rating Reiterated by FinnCap (DPH)
Dechra Pharmaceuticals (LON:DPH)‘s stock had its “buy” rating restated by equities researchers at FinnCap in a research report issued on Monday, AnalystRatings.NET reports. They currently have a GBX 800 ($13.18) price target on the stock. FinnCap’s price objective would indicate a potential upside of 14.29% from the stock’s previous close.
Dechra Pharmaceuticals (LON:DPH) opened at 700.00 on Monday. Dechra Pharmaceuticals has a one year low of GBX 604.00 and a one year high of GBX 791.50. The stock’s 50-day moving average is GBX 694. and its 200-day moving average is GBX 696.1. The company’s market cap is £610.1 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at Panmure Gordon reiterated a “buy” rating on shares of Dechra Pharmaceuticals in a research note to investors on Monday, January 6th. They now have a GBX 850 ($14.01) price target on the stock. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 775 ($12.77).
Dechra Pharmaceuticals PLC (LON:DPH) is an international veterinary pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.